Zevtera na rigakafi (Ceftobiprole medocaril) FDA ta amince da ita don maganin CABP, ABSSSI da SAB. 

cephalosporin na ƙarni na biyar mai faɗi kwayoyin, Zavtera (Ceftobiprole medocaril sodium Inj.) an yarda da shi FDA¹ domin magani na cututtuka guda uku wato.  

1. Staphylococcus aureus cututtuka na jini (bacteremia) (SAB), ciki har da wadanda ke da endocarditis na gefen dama;  

2. m kwayoyin fata da fata tsarin cututtuka (ABSSSI); kuma  

3. ciwon huhu na kwayan cuta (CABP).  

Wannan ya biyo bayan sakamako mai gamsarwa na lokaci 3 na gwaji na asibiti.  

An amince da Ceftobiprole medocaril a yawancin ƙasashen Turai, da kuma Kanada don maganin ciwon huhu da aka samu a asibiti (ban da ciwon huhu da aka samu na iska) da ciwon huhu da al'umma ke samu a cikin manya.².  

A Burtaniya, Ceftobiprole medocaril a halin yanzu yana cikin gwajin asibiti na kashi III³ duk da haka, an yarda da shi don ƙuntataccen amfani a cikin NHS Scotland⁴.  

A cikin EU, ya bayyana a cikin Ƙungiyar Tarayyar na samfuran magunguna da aka ƙi don amfanin ɗan adam⁵. 

Ceftobiprole medocaril, ƙarni na biyar m-bakan cephalosporin yana da tasiri akan kwayoyin cutar Gram-tabbatacce irin su methicillin-resistant Staphylococcus aureus da penicillin-resistant Streptococcus pneumoniae, da kuma kwayoyin cutar Gram-korau irin su Pseudomonas aeruginosa. An gano yana da amfani wajen magance ciwon huhu da al'umma suka samu da ciwon huhu, sai dai ciwon huhu da ke da alaƙa da iska.^6,7. 

*** 

References:  

1. FDA Fitar labarai. FDA Ya Amince Sabo Kwayar rigakafi don Amfani daban-daban guda uku. An buga 03 Afrilu 2024. Akwai a https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses/ 

2. Jame W., Basgut B., da Abdi A., 2024. Ceftobiprole mono-therapy tare da hadewa ko tsarin rashin haɗin kai na daidaitattun maganin rigakafi don maganin cututtuka masu rikitarwa: nazari na yau da kullum da meta-bincike. Bincike ilimin halittu kanana da Cututtuka masu Yaduwa. Akwai akan layi 16 Maris 2024, 116263. DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116263  

3. NIHR. Takaitaccen Bayanin Fasahar Kiwon Lafiya Nuwamba 2022. Ceftobiprole medocaril don kula da ciwon huhu da aka samu a asibiti ko ciwon huhu da al'umma ke samu wanda ke buƙatar asibiti a cikin yara. Akwai a https://www.io.nihr.ac.uk/wp-content/uploads/2023/04/28893-Ceftobiprole-medocaril-for-pneumonia-V1.0-NOV2022-NONCONF.pdf  

4. Ƙungiyar Magunguna ta Scotland. Ceftobiprole medocaril (Zevtera). Akwai a https://www.scottishmedicines.org.uk/medicines-advice/ceftobiprole-medocaril-zevtera-resubmission-94314/  

5. Hukumar Tarayyar Turai. Rijistar Tarayyar na samfuran magunguna da aka ƙi don amfanin ɗan adam. An sabunta ta ƙarshe ranar 21 ga Fabrairu 2024. Akwai a https://ec.europa.eu/health/documents/community-register/html/ho10801.htm 

6. Lupia T., et al 2022. Ra'ayin Ceftobiprole: Halin Yanzu da Mahimman Alamun Gaba. Kwayoyi masu kare cututtuka Juzu'i na 10 Fitowa ta 2. DOI: https://doi.org/10.3390/antibiotics10020170  

7. Méndez1 R., Latorre A., da González-Jiménez P., 2022. Ceftobiprole medocaril. Rev Esp Quimioter. 2022; 35 (Kashi na 1): 25–27. An buga online 2022 Apr 22. DOI: https://doi.org/10.37201/req/s01.05.2022  

***